An anticoagulant should always be used in the established tail arterial catheter and to re-establish the infusion line in a lateral tail vein immediately before the next study.

About this issue Abstract AbstractChronic infusion of prostacyclin (PGI2) via a Broviac central venous line (CVL) is attended by risk of CVL-related complications, but we know of only one report ...

Panelists discuss how NCCN guidelines are expected to incorporate quadruplet-based regimens as reasonable treatment approaches for transplant-ineligible patients, while emphasizing the need for ...

Now, Vyalev (foscarbidopa and foslevodopa) has become the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's ...

The disease primarily affects middle-aged women and has a poor long-term prognosis despite therapeutic advances.

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

Panelists discuss how the rapid adoption of subcutaneous (SubQ) oncology therapies creates challenges around clinical autonomy, infusion center sustainability, patient experience, and reimbursement ...

Medical analysis equipment maker Waters is combining with a unit of Becton Dickinson in a complex spin-merge. At a discount ...

It delivers a continuous subcutaneous infusion of levodopa-carbidopa—the gold-standard medication for Parkinson’s—through a compact pump connected to the skin.

JSW Paints secures funding for Akzo Nobel India buy through promoter infusion and PE funds, aiming for market growth.

AbbVie has launched its Produodopa for Parkinson’s in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the disease.